- Home
- RPID vs ACRS Comparison
RPID vs ACRS Comparison
Compare RPID & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPID
- ACRS
- Stock Information
- Founded
- RPID 2006
- ACRS 2012
- Country
- RPID United States
- ACRS United States
- Employees
- RPID N/A
- ACRS N/A
- Industry
- RPID Medical Specialities
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- RPID Health Care
- ACRS Health Care
- Exchange
- RPID Nasdaq
- ACRS Nasdaq
- Market Cap
- RPID 138.9M
- ACRS 165.7M
- IPO Year
- RPID 2021
- ACRS 2015
- Fundamental
- Price
- RPID $3.49
- ACRS $1.43
- Analyst Decision
- RPID Buy
- ACRS Strong Buy
- Analyst Count
- RPID 1
- ACRS 8
- Target Price
- RPID $8.00
- ACRS $9.71
- AVG Volume (30 Days)
- RPID 84.2K
- ACRS 1.3M
- Earning Date
- RPID 08-01-2025
- ACRS 08-06-2025
- Dividend Yield
- RPID N/A
- ACRS N/A
- EPS Growth
- RPID N/A
- ACRS N/A
- EPS
- RPID N/A
- ACRS N/A
- Revenue
- RPID $29,645,000.00
- ACRS $17,777,000.00
- Revenue This Year
- RPID $18.54
- ACRS N/A
- Revenue Next Year
- RPID $20.55
- ACRS $11.77
- P/E Ratio
- RPID N/A
- ACRS N/A
- Revenue Growth
- RPID 28.36
- ACRS N/A
- 52 Week Low
- RPID $0.58
- ACRS $1.05
- 52 Week High
- RPID $4.04
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- RPID 54.22
- ACRS 46.21
- Support Level
- RPID $3.41
- ACRS $1.34
- Resistance Level
- RPID $3.62
- ACRS $1.66
- Average True Range (ATR)
- RPID 0.24
- ACRS 0.10
- MACD
- RPID -0.03
- ACRS -0.01
- Stochastic Oscillator
- RPID 62.03
- ACRS 16.67
About RPID Rapid Micro Biosystems Inc.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.